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To the Editor
Highly penetrant mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene 
have been identified as major risk factors for melanoma, and they account for between 20% 
and 50% of familial cases (Kefford et al. 1999, Goldstein and Tucker 2001). Pathogenic 
germline mutations at CDKN2A have been associated with malignancies other than 
melanoma, including: breast and pancreatic cancers (Borg et al. 2000, Goldstein et al. 2006, 
de Snoo et al. 2008, Ghiorzo et al. 2012, Potrony et al. 2014), smoking-related cancers of the 
head and neck, lung cancer, and gastroesophageal carcinomas (Helgadottir et al. 2014, Potjer 
et al. 2015), as well as central nervous system tumors (Petronzelli et al. 2001, Pasmant et al. 
2007). Moreover, there is recent evidence to suggest that familial melanoma cases who are 
wildtype for CDKN2A are not at increased risk for non-melanoma cancers in contrast to 
pathogenic mutation carriers (Helgadottir et al. 2014). Distinguishing familial melanoma 
cases with and without pathogenic CDKN2A mutations may serve to heighten awareness of 
increased risk for other cancers among carriers in melanoma families. Identifying 
histopathological and other host features that are associated with inherited pathogenic 
CDKN2A mutations may aide in this pursuit and also serve to better characterize melanoma 
heterogeneity and elucidate important pathobiological differences between carriers and non-
carriers of pathogenic CDKN2A mutations.
We studied affected members of melanoma families assembled across centers of the 
GenoMEL consortium and evaluated differences in host and histopathological tumor 
characteristics between carriers and non-carriers of pathogenic CDKN2A mutations. Written 
informed consent was obtained for each participant, and individual GenoMEL study center 
investigations were conducted after approval by their respective institutional review boards. 
To our knowledge, this study is the largest of its kind and incorporates familial melanoma 
cases from diverse geographical populations.
GenoMEL participants who signed informed consent were asked about their personal 
melanoma history and to complete a self-administered questionnaire asking about 
phenotypic characteristics including: hair color, eye color, freckling, nevi, burnability (effect 
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of acute sun exposure on skin), and tanning ability (effect of chronic sun exposure on skin). 
A melanoma family was defined by the presence of three or more cases of verified 
melanoma, or two cases of verified melanoma in first-degree relatives. Histopathological 
data were abstracted from pathology or other clinical reports; a centralized pathology review 
was not performed. Germline DNA was screened for mutations in CDKN2A (exons 1α, 1β, 
2 and 3) as previously described (Harland et al. 2008), and pathogenicity was assigned 
according to Supplemental Table 1. Pathogenicity was based on demonstrated (i.e. 
published) impact on the biological functioning of CDK2NA, and putative pathogenicity of 
specific mutations was based on evidence of cosegregation within melanoma families or 
bioinformatically inferred impact on CDKN2A function. Participants were classified based 
on presence or absence of a pathogenic or putatively pathogenic variant.
We tested whether differences in levels of histopathological or phenotypic factors exist by 
CDKN2A pathogenic mutation carrier status (α=0.05). Analyses were adjusted for age at 
diagnosis, gender, study center, and number of affected members per family, and we 
accounted for the non-independence of observations arising from familial clustering within 
study center using the repeated subject statement. We also adjusted for presence of any 
melanocortin-1 receptor (MC1R) variant.
There were 1,928 and 1,696 verified cases with CDKN2A genotype data who contributed 
histopathological and phenotypic data to analyses respectively. Associations between 
CDKN2A mutational status and age at diagnosis (Ptrend<0.0001), multiple primary 
melanomas (MPM) (P<0.0001), and histologic subtype (P=0.003) were statistically 
significant after adjustment for covariates and Bonferroni correction (Table 1). Pathogenic 
mutation carriers were younger at diagnosis and demonstrated higher proportions of MPM 
and superficial spreading melanomas (SSM) compared to wildtype/nonpathogenic mutation 
carriers. We also observed statistically significant differences between pathogenic and 
wildtype/non-pathogenic CDKN2A mutation carriers with respect to sun burning 
(Ptrend=0.02) and skin type (P=0.04) after adjustment for covariates; pathogenic mutation 
carriers were significantly less likely to develop severe burns with blistering and more likely 
to report a darker skin type compared to wildtype/non-pathogenic mutation carriers (Table 
2). Neither factor remained significant after Bonferroni correction. Frequencies and p-values 
for CDKN2A association analyses involving all tested histopathological and phenotypic 
characteristics are reported in Supplemental Tables 2 and 3 respectively.
This study reports an analysis of data collected across all GenoMEL centers using a 
common protocol. Overall, phenotypic and tumor features were similar among affected 
family members with and without pathogenic mutations in CDKN2A. Nevertheless, these 
groups were differentiated by some of the same factors that distinguish familial melanomas 
from those arising in the general population (Florell et al. 2005): pathogenic mutation 
carriers were younger at diagnosis (median age at diagnosis: 38 years vs. 46 years) and they 
had a greater likelihood of developing multiple melanomas (average number of melanomas: 
2.3 vs. 1.4) compared to wildtype/non-pathogenic mutation carriers, findings consistent with 
results reported by FitzGerald et al. (FitzGerald et al. 1996). The preponderance of SSM 
observed among pathogenic mutation carriers is consistent with a recent GenoMEL study by 
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Sargen et al. in which a blinded review of a limited subset of tumors was un (Sargen et al. 
2015).
It has been suggested that heterogeneity within melanoma is due in part to distinct etiologic 
pathways—one characterized by increased numbers of nevi, lesion presentation on the trunk, 
and intermittent sun exposure; and one characterized by fewer nevi, lesion presentation on 
the head and neck, and chronic sun exposure. Our results provide some evidence for 
differential effects of acute sun exposure between those with and without pathogenic 
CDKN2A mutations and may suggest that pathogenic mutation carriers are less prone to 
severe sun burns, a result which is consistent with our observation of a higher proportion of 
darker skin types reported by pathogenic mutation carriers. However, no differences in nevi 
or body site of lesion were observed.
Notable limitations of our study were: inability to evaluate the impact of inherited variation 
at other loci on histopathological and phenotypic factors, ascertainment and sampling of 
families at some centers was not population-based, centers obtained data to varying degrees, 
and a lack of centralized pathology review. To address the latter limitation, we conducted a 
sensitivity analysis restricting histopathological data to those reported by 
dermatopathologists, who are more likely to report on a fuller spectrum of features relevant 
to melanoma pathology; the results were not appreciably different from those obtained in 
our main analysis.
In summary, familial cases with and without pathogenic CDKN2A mutations exhibit similar 
distributions of phenotypic and tumor characteristics. However, cases with pathogenic 
mutations may be distinguished by features including: younger age at diagnosis, multiple 
melanoma diagnoses, SSM subtype, and a lack of severe sun burns.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Distribution of host and histopathological tumor characteristics among cases of verified cutaneous melanoma 
belonging to melanoma families1 overall and according to CDKN2A pathogenicity.
Overall with CDKN2A Pathogenic CDKN2A 
mutation carrier





N=1,928 N=670 N=1,258 P-value2
n (%) n (%) n (%)
Age at Diagnosis <0.0001
< 30 years 367 (19) 169 (25) 198 (16)
30–39 years 469 (24) 198 (30) 271 (22)
40–49 years 384 (20) 138 (21) 246 (20)
50–59 years 362 (19) 95 (14) 267 (21)
60–69 years 238 (12) 49 (7) 189 (15)
≥ 70 years 103 (5) 17 (3) 86 (7)
missing 5 4 1
Multiple Primary Melanomas <0.0001
No 1,297 (67) 346 (52) 951 (76)
Yes 631 (33) 324 (48) 307 (24)
missing 0 0 0
Breslow Depth (mm)† 0.03
in situ 229 (15) 90 (16) 139 (14)
0.01–1.00 917 (59) 343 (62) 574 (57)
1.01–2.00 246 (16) 76 (14) 170 (17)
2.01–4.00 127 (8) 35 (6) 92 (9)
> 4.00 44 (3) 10 (2) 34 (3)
missing 365 116 249
Histologic Subtype 0.003
SSM 879 (71) 378 (73) 501 (70)
LMM 49 (4) 10 (2) 39 (5)
NM 104 (8) 31 (6) 73 (10)
NOS 177 (14) 90 (18) 87 (13)
Other‡ 24 (2) 6 (1) 18 (3)
missing 695 155 540
1
A melanoma family is defined by three or more blood relatives with verified cutaneous melanoma diagnoses or two first degree relatives with 
verified cutaneous melanoma diagnoses. Verification was made by: pathology report (77%), physician letter or clinical document verifying 
melanoma diagnosis (20%), cancer registry data (3%), or death certificate (<1%). Individuals who were missing data for all histopathological 
features were excluded from analysis (n=180).
2
P-value corresponds to a score test with α=0.05 testing for a difference in proportions between wildtype/non-pathogenic and pathogenic 
CDKN2A mutation carriers with respect to a histopathological feature, with adjustment for age at diagnosis (continuous), sex, number of affected 
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members per family, study center and familial clustering within study center. All analyses were conducted using SAS v.9.3 (SAS Institute, Cary, 
NC).
†
Adjusted for body site of melanoma
‡
Includes acral lentiginous melanomas and rare subtypes including: nevoid, spitzoid, and desmoplastic melanomas
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Table 2
Distribution of phenotypic characteristics among cases of verified cutaneous melanoma belonging to 
melanoma families1 overall and according to CDKN2A pathogenicity.
Overall with CDKN2A Pathogenic CDKN2A 
mutation carrier





N=1,696 N=604 N=1,092 P-value2
n (%) n (%) n (%)
Effect of Acute Sun 
Exposure on Skin
0.02
Tan, no burn 47 (4) 18 (5) 29 (3)
Mild burn 479 (35) 156 (39) 323 (33)
Burn, then peel 584 (43) 168 (42) 416 (43)
Severe burn, then blister 263 (19) 56 (14) 207 (21)
missing 323 206 117
Skin Type 0.04
Brown/Olive 130 (8) 62 (11) 68 (6)
Fair 1,144 (71) 384 (68) 760 (72)
Very Fair 336 (21) 115 (21) 221 (21)
missing 86 43 43
1
A melanoma family is defined by three or more blood relatives with verified cutaneous melanoma diagnoses or two first degree relatives with 
verified cutaneous melanoma diagnoses. Verification was made by: pathology report (77%), physician letter or clinical document verifying 
melanoma diagnosis (20%), cancer registry data (3%), or death certificate (<1%). Individuals who were missing data for all phenotypic 
characteristics were excluded from analysis (n=412).
2
P-value corresponds to a score test with α=0.05 testing for a difference in proportions between wildtype/non-pathogenic and pathogenic 
CDKN2A mutation carriers with respect to a phenotypic characteristic, adjusted for age at diagnosis (continuous), sex, MC1R variant carriage, 
number of affected members per family, study center and familial clustering within study center. All analyses were conducted using SAS v.9.3 
(SAS Institute, Cary, NC).
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